Effects of alternate-day fasting on body weight and dyslipidaemia in patients with non-alcoholic fatty liver disease: a randomised controlled trial
Cai H, Qin YL, Shi ZY, Chen JH, Zeng MJ, Zhou W, Chen RQ, Chen ZY
BMC gastroenterology · 154 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Funding not disclosed
Publication
- Published
- 2019-12-01 · BMC Gastroenterol · vol. 19 · issue 1 · p. 219
- Publisher
- BioMed Central
- Cited
- 204 citations · more than 99% of similar papers · 9.8× the field average
- Impact
- Top 10% most cited in its field
- References
- 28 works
- Access
- Open access (journal) · CC-BY
- Research areas
- Dietary Effects on Health · Diet and metabolism studies · Enhanced Recovery After Surgery
- Keywords
- Medicine, Internal medicine, Fatty liver, Intermittent fasting, Body mass index, Weight loss, Endocrinology, Anthropometry, Hepatology, Body weight, Cholesterol, Animal science, Gastroenterology, Obesity, Disease, Biology
- MeSH
- humans, metabolic diseases, body weight, weight loss, cholesterol, triglycerides, fasting, risk factors, feeding behavior, hunger, body composition, energy intake, time factors, adult, female, male, adiposity, dyslipidemias, non-alcoholic fatty liver disease, outcome assessment, health care
8 authors
From CN
- Hua “Linda” CaiHunan Normal University
- Yuelan QinHunan Normal University
- Zeya ShiHunan Normal University
- Jinhui ChenHunan Normal University
- Min-Jie ZengHunan Normal University
- Wei ZhouHunan Normal University
Abstract
Background
Alternate-day fasting (ADF) is a novel diet therapy that may achieve reduction in body weight and improvement of dyslipidaemia, but the impact of this diet on patients with non-alcoholic fatty liver disease (NAFLD) remains unknown. The aim of this study was to evaluate the effects of ADF on the body weight and lipid profile of individuals with NAFLD.
Methods
NAFLD patients (n = 271) were randomised to the ADF group, time-restricted feeding (TRF) group, or the control group and subjected to the respective diet for 12 weeks. Anthropometric measurements (body weight, fat mass/fat-free mass) were performed, and plasma lipids were analysed enzymatically.
Results
Within 4 weeks, the body weight decreased significantly (P < 0.001) in the ADF group by 4.56 ± 0.41 kg (6.1 ± 0.5%) and the TRF group by 3.62 ± 0.65 kg (4.83 ± 0.9%) compared to the control group, and it decreased even more after 12 weeks in both groups (ADF: - 4.04 ± 0.54 kg, 5.4 ± 0.7%; TRF: - 3.25 ± 0.67 kg, 4.3 ± 0.9%). Fat mass was significantly reduced by ADF (- 3.49 ± 0.37 kg; 11 ± 1.2%) and TRF (- 2.91 ± 0.41 kg; 9.6 ± 1.3%), with ADF leading to a further reduction in fat mass after 12 weeks (- 3.48 ± 0.38 kg; 11 ± 1.2%). Total cholesterol was significantly decreased at both time points in the ADF group (- 0.91 ± 0.07 mmol/L; 18.5 ± 1.5%) compared to the control and TRF groups. Both ADF (- 0.64 ± 0.06 mmol/L; 25 ± 1.9%) and TRF (0.58 ± 0.07 mmol/L; 20 ± 1.7%) achieved a significant reduction in serum triglycerides (P < 0.001) after 12 weeks. Changes in fat free mass, HDL, LDL, fasting insulin, glucose, liver stiffness, and systolic or diastolic blood pressure did not differ between the groups.
Conclusions
ADF appears to be an effective diet therapy for individuals with NAFLD that can achieve weight loss and improvement of dyslipidaemia within a relatively short period of time (4 to 12 weeks). Potential preventive effects of ADF on cardiovascular disease need to be confirmed by future investigations.
Trial registration
ChiCTR1900024411, this trial was retrospectively registered on July 10, 2019.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.